Company intelligence / Profile preview
MetaFines
Seongnam-si, Gyeonggi-do, South Koreapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
MetaFines’ lead asset, ASCA101, has completed a Phase I open-label study in patients with advanced solid tumors to evaluate safety, tolerability, PK/PD, and antitumor effect. The company’s approach focuses on disrupting cancer cell metabolism through simultaneous uptake of different compounds to overcome drug resistance and improve efficacy while maintaining low toxicity.
- Therapeutic areas
- OncologyNeurologyMetabolic Disorders
- Modalities
- Small moleculesNew Chemical Entities (NCE)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on MetaFines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetaFines.